SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

線維腺腫市場調査レポート

Fibroadenoma Market Research Report

Fibroadenoma Market Research Report Information by Type (Simple Fibroadenoma and Complex Fibroadenoma), by Diagnosis & Treatment (Diagnosis [Ultrasound Scan, Mammography, and Biopsy] and Treatment [Cryoablation, High Intensity Focused Ultrasound (HIFU), Lumpectomy, and Drugs {Dydrogesterone, Medroxyprogesterone, Selective Estrogen Receptor Modulators, and Others}], by End User (Hospital and Clinics, Diagnostic Centers, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032
出版年月2024年7月
ページ数136
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

Report Overview

Fibroadenoma Market Research Report Information by Type (Simple Fibroadenoma and Complex Fibroadenoma), by Diagnosis & Treatment (Diagnosis [Ultrasound Scan, Mammography, and Biopsy] and Treatment [Cryoablation, High Intensity Focused Ultrasound (HIFU), Lumpectomy, and Drugs {Dydrogesterone, Medroxyprogesterone, Selective Estrogen Receptor Modulators, and Others}], by End User (Hospital and Clinics, Diagnostic Centers, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) – Forecast till 2032

線維腺腫市場調査レポート : タイプ (単純性線維腺腫と複雑性線維腺腫)、診断と治療 {診断 [超音波スキャン、マンモグラフィー、および生検] および治療 [冷凍アブレーション、高密度焦点超音波 (HIFU)、肺切除術]、および薬物 [ジドロゲステロン、メドロキシプロゲステロン、選択的エストロゲン受容体モジュレーター] 、その他}、エンドユーザー (病院および診療所、診断センター、その他) および地域 (北米、ヨーロッパ、アジア太平洋、RoW) – 2032年までの予測

Market Dynamics

In 2023, the fibroadenoma market is expected to be USD 0.71 billion. Exhibiting a compound annual growth rate (CAGR) of 6.36%, the Fibroadenoma Market industry is expected to rise from USD 0.77 billion in 2024 to USD 1.34 billion by 2032.

The main forces driving the expansion of the fibroedema market are public education initiatives raising awareness of fibroadenoma and growing prevalence of fibroadenoma among women.

One clear main driver in the fibroadenoma market is growing public knowledge of fibroadenoma resulting from public education programs. Public education initiatives are quite important in guiding women on the indicators and symptoms of fibroadenoma. This increased consciousness motivates women to get regular breast exams and screenings as well as to engage in proactive health-seeking activity. Timeliness of action and suitable therapy of fibroadenomas depend on early discovery. Public education initiatives also serve to debunk false ideas and misunderstandings about breast lumps, therefore reducing unwarranted tension and concern related with such results.

Moreover, the expansion of the fibroadenoma market is clearly driven by the development of better diagnostic tools. Timely and suitable medical action depends on accurate identification of fibroadenomas, thus developments in diagnostic instruments have greatly improved the detection accuracy. Improved diagnostic methods let doctors find fibroadenomas earlier on. Implementing prompt and focused treatment plans, lowering the possibility for complications, and enhancing patient outcomes all depend on early diagnosis of this kind. The diagnosis approach to fibroadenomas has been transformed by the advent and improvement of non-invasive imaging technologies including magnetic resonance imaging (MRI) and ultrasonic waves.

Insights of Market Segments

Type dictates that the Fibroadenoma Market consists of simple and complex fibroadenoma.

The fibroadenoma market is split based on diagnosis and treatment.

The fibroadenoma market is divided depending on end user into others, ambulatory surgical centers, and hospitals and clinics.

Regional Analysis

Thanks to the sophisticated diagnostic technologies and medical infrastructure as well as reimbursement policies and insurance coverage, North America accounted for the biggest market share of about 38.49% in 2022. Moreover, compared to other areas, North Americans have easier access to healthcare and show more awareness of health problems. Consequently, even in asymptomatic instances, more frequent visits and fibroadenoma diagnosis follow from this.

Because minimally invasive treatments for fibroadenomas including cryoablation and vacuum-assisted excision—particularly strong in Europe—show great growth in the Europe fibroadenoma market over the projected year, i.e., 2024–2032. The local hospitals and clinics draw people looking for less intrusive choices since they are ready to execute these operations.

The fastest-growing area throughout the projection period is the Asia-Pacific fibroadenoma market since regular expansion of breast diagnosis and treatment equipment drives frequent launch of machines. IceCure Medical LTD. declared in May 2023 that ProSense was installed and opened at Kovai Medical Center and Hospital (“KMCH”) in India.

Main Players

Important companies in the Fibroadenoma Market are GE Healthcare (US), Koninklijke Philips N.V. (Germany), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Canon Medical Systems Corporation (Japan), Dilon Technologies (US), Pfizer, Inc. (US), IceCure Medical (Israel), Alpinion Medical Systems (South Korea), and Fujifilm Holdings Corporation (Japan).

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 DATA MINING PROCESS

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 SECONDARY RESEARCH DATA FLOW:

3.5 PRIMARY RESEARCH:

3.5.1 PRIMARY RESEARCH DATA FLOW:

3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED

3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 REVENUE ANALYSIS APPROACH

3.7 DATA FORECASTING

3.7.1 DATA FORECASTING TECHNIQUE

3.8 DATA MODELING

3.8.1 MICROECONOMIC FACTOR ANALYSIS:

3.8.2 DATA MODELING:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 INCREASED AWARENESS ABOUT FIBROADENOMA THROUGH PUBLIC EDUCATION CAMPAIGNS

4.2.2 DEVELOPMENT OF IMPROVED DIAGNOSTIC TECHNIQUES TO ACCURATELY IDENTIFY FIBROADENOMA

4.2.3 INCREASING PREVALENCE OF FIBROADENOMA AMONG WOMEN

4.3 RESTRAINTS

4.3.1 HIGH COST OF TREATMENT OF FIBROADENOMA

4.4 OPPORTUNITY

4.4.1 RESEARCH INTO NEW TREATMENT OPTIONS FOR FIBROADENOMA, SUCH AS MINIMALLY INVASIVE SURGICAL PROCEDURES OR MEDICATIONS

4.4.2 GROWING ADOPTION OF MINIMALLY INVASIVE SURGICAL PROCEDURES FOR THE TREATMENT OF FIBROADENOMA

4.5 CHALLENGES

4.5.1 NON-LIFE THREATENING NATURE OF FIBROADENOMAS

4.6 IMPACT ANALYSIS OF COVID-19

4.6.1 IMPACT 0N OVERALL FIBROADENOMA INDUSTRY

4.6.1.1 ECONOMIC IMPACT

4.6.2 IMPACT ON GLOBAL FIBROADENOMA MARKET

4.6.3 IMPACT ON THE SUPPLY CHAIN OF FIBROADENOMA

4.6.4 IMPACT ON MARKET DEMAND OF FIBROADENOMA

4.6.4.1 IMPACT DUE TO RESTRICTIONS/LOCKDOWN

4.6.4.2 CONSUMER SENTIMENTS

4.6.5 IMPACT ON PRICING OF FIBROADENOMA

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 RAW MATERIALS

5.1.2 MANUFACTURING / PRODUCTION/ PROCESSING

5.1.3 DISTRIBUTION CHANNEL

5.1.4 END-USER

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

6 GLOBAL FIBROADENOMA MARKET, BY TYPE

6.1 INTRODUCTION

6.2 SIMPLE FIBROADENOMA

6.3 COMPLEX FIBROADENOMA

7 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT

7.1 INTRODUCTION

7.2 DIAGNOSIS

7.2.1 ULTRASOUND SCAN

7.2.2 MAMMOGRAPHY

7.2.3 BIOPSY

7.3 TREATMENT

7.3.1 CRYOBLATION

7.3.2 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU)

7.3.3 LUMPECTOMY

7.3.4 DRUGS

7.3.4.1 DYDROGESTERONE

7.3.4.2 MEDROXYPROGESTERONE

7.3.4.3 SELECTIVE ESTROGEN RECEPTOR MODULATORS

7.3.4.4 OTHERS

8 GLOBAL FIBROADENOMA MARKET, BY END-USER

8.1 INTRODUCTION

8.2 HOSPITAL AND CLINICS

8.3 DIAGNOSTIC CENTERS

8.4 OTHERS

9 GLOBAL FIBROADENOMA MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.2.3 MEXICO

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 UK

9.3.4 SPAIN

9.3.5 ITALY

9.3.6 REST OF EUROPE

9.4 ASIA PACIFIC

9.4.1 CHINA

9.4.2 INDIA

9.4.3 JAPAN

9.4.4 SOUTH KOREA

9.4.5 AUSTRALIA

9.4.6 REST OF ASIA PACIFIC

9.5 REST OF THE WORLD

9.5.1 SOUTH AMERICA

9.5.2 MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION

10.2 COMPETITION DASHBOARD

10.3 MARKET SHARE ANALYSIS, 2022

10.4 PUBLIC PLAYERS STOCK SUMMARY

10.5 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.5.1 PRODUCT LAUNCH

10.5.2 PARTNERSHIP

10.5.3 EXPANSION

11 COMPANY PROFILES

11.1 GE HEALTHCARE

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGY

11.2 KONINKLIJKE PHILIPS N.V.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGY

11.3 SHIMADZU CORPORATION

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGY

11.4 SIEMENS HEALTHINEERS

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGY

11.5 CANON MEDICAL SYSTEMS CORPORATION

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 SWOT ANALYSIS

11.5.5 KEY DEVELOPMENTS

11.5.6 KEY STRATEGY

11.6 DILON TECHNOLOGIES

11.6.1 COMPANY OVERVIEW

11.6.2 PRODUCTS OFFERED

11.6.3 SWOT ANALYSIS

11.6.4 KEY DEVELOPMENTS

11.6.5 KEY STRATEGY

11.7 PFIZER, INC

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGY

11.8 ICECURE MEDICAL

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGY

11.9 ALPINION MEDICAL SYSTEMS

11.9.1 COMPANY OVERVIEW

11.9.2 PRODUCTS OFFERED

11.9.3 KEY DEVELOPMENTS

11.9.4 SWOT ANALYSIS

11.9.5 KEY STRATEGY

11.10 FUJIFILM HOLDINGS CORPORATION

11.10.1 COMPANY OVERVIEW

11.10.2 PRODUCTS OFFERED

11.10.3 KEY DEVELOPMENTS

11.10.4 SWOT ANALYSIS

11.10.5 KEY STRATEGY

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

List of Tables

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT

TABLE 2 GLOBAL FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 3 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY SIMPLE FIBROADENOMA, 2019-2032 (USD MLLION)

TABLE 4 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY COMPLEX FIBROADENOMA, 2019-2032 (USD MLLION)

TABLE 5 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 6 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY DIAGNOSIS, 2019-2032 (USD MLLION)

TABLE 7 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY TREATMENT, 2019-2032 (USD MLLION)

TABLE 8 GLOBAL FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 9 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY HOSPITAL AND CLINICS, 2019-2032 (USD MLLION)

TABLE 10 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY DIAGNOSTIC CENTERS, 2019-2032 (USD MLLION)

TABLE 11 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY OTHERS, 2019-2032 (USD MLLION)

TABLE 12 GLOBAL FIBROADENOMA MARKET, BY REGION, 2019-2032 (USD MLLION)

TABLE 13 NORTH AMERICA FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)

TABLE 14 NORTH AMERICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 15 NORTH AMERICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 16 NORTH AMERICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 17 US FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 18 US FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 19 US FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 20 CANADA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 21 CANADA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 22 CANADA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 23 MEXICO FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 24 MEXICO FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 25 MEXICO FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 26 EUROPE FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)

TABLE 27 EUROPE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 28 EUROPE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 29 EUROPE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 30 GERMANY FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 31 GERMANY FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 32 GERMANY FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 33 FRANCE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 34 FRANCE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 35 FRANCE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 36 UK FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 37 UK FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 38 UK FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 39 SPAIN FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 40 SPAIN FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 41 SPAIN FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 42 ITALY FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 43 ITALY FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 44 ITALY FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 45 REST OF EUROPE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 46 REST OF EUROPE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 47 REST OF EUROPE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 48 ASIA PACIFIC FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)

TABLE 49 ASIA PACIFIC FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 50 ASIA PACIFIC FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 51 ASIA PACIFIC FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 52 CHINA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 53 CHINA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 54 CHINA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 55 INDIA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 56 INDIA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 57 INDIA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 58 JAPAN FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 59 JAPAN FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 60 JAPAN FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 61 SOUTH KOREA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 62 SOUTH KOREA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 63 SOUTH KOREA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 64 AUSTRALIA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 65 AUSTRALIA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 66 AUSTRALIA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 67 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 68 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 69 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 70 REST OF THE WORLD FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)

TABLE 71 REST OF THE WORLD FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 72 REST OF THE WORLD FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 73 REST OF THE WORLD FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 74 SOUTH AMERICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 75 SOUTH AMERICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 76 SOUTH AMERICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 77 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)

TABLE 78 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)

TABLE 79 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)

TABLE 80 PUBLIC PLAYERS STOCK SUMMARY

TABLE 81 PRODUCT LAUNCH

TABLE 82 PARTNERSHIP

TABLE 83 EXPANSION

TABLE 84 GE HEALTHCARE: PRODUCTS OFFERED

TABLE 85 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED

TABLE 86 SHIMADZU CORPORATION: PRODUCTS OFFERED

TABLE 87 SHIMADZU CORPORATION: KEY DEVELOPMENTS

TABLE 88 SIEMENS HEALTHINEERS: PRODUCTS OFFERED

TABLE 89 SIEMENS HEALTHINEERS: KEY DEVELOPMENTS

TABLE 90 CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS OFFERED

TABLE 91 CANON MEDICAL SYSTEMS CORPORATION: KEY DEVELOPMENTS

TABLE 92 DILON TECHNOLOGIES: PRODUCTS OFFERED

TABLE 93 DILON TECHNOLOGIES: KEY DEVELOPMENTS

TABLE 94 PFIZER, INC: PRODUCTS OFFERED

TABLE 95 ICECURE MEDICAL: PRODUCTS OFFERED

TABLE 96 ALPINION MEDICAL SYSTEMS: PRODUCTS OFFERED

TABLE 97 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED

List of Figures

LIST OF FIGURES

FIGURE 1 GLOBAL FIBROADENOMA MARKET: STRUCTURE

FIGURE 2 GLOBAL FIBROADENOMA MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)

FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032)

FIGURE 4 PORTER’S FIVE FORCES MODEL: GLOBAL FIBROADENOMA MARKET

FIGURE 5 GLOBAL FIBROADENOMA MARKET, BY TYPE, SEGMENT ATTRACTIVENESS ANALYSIS

FIGURE 6 GLOBAL FIBROADENOMA MARKET, BY TYPE, 2022 (% SHARE)

FIGURE 7 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, SEGMENT ATTRACTIVENESS ANALYSIS

FIGURE 8 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2022 (% SHARE)

FIGURE 9 GLOBAL FIBROADENOMA MARKET, BY END-USER, SEGMENT ATTRACTIVENESS ANALYSIS

FIGURE 10 GLOBAL FIBROADENOMA MARKET, BY END-USER, 2022 (% SHARE)

FIGURE 11 GLOBAL FIBROADENOMA MARKET, BY REGION, 2022 (% SHARE)

FIGURE 12 NORTH AMERICA MARKET: COMPARATIVE ANALYSIS

FIGURE 13 NORTH AMERICA MARKET: SWOT ANALYSIS

FIGURE 14 NORTH AMERICA FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)

FIGURE 15 EUROPE MARKET: COMPARATIVE ANALYSIS

FIGURE 16 EUROPE FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)

FIGURE 17 EUROPE MARKET: SWOT ANALYSIS

FIGURE 18 ASIA PACIFIC MARKET: COMPARATIVE ANALYSIS

FIGURE 19 ASIA PACIFIC FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)

FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS

FIGURE 21 REST OF THE WORLD MARKET: COMPARATIVE ANALYSIS

FIGURE 22 REST OF THE WORLD FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)

FIGURE 23 REST OF THE WORLD MARKET: SWOT ANALYSIS

FIGURE 24 COMPETITOR DASHBOARD: GLOBAL FIBROADENOMA MARKET

FIGURE 25 GLOBAL FIBROADENOMA MARKET: COMPETITIVE ANALYSIS, 2022

FIGURE 26 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 GE HEALTHCARE: SWOT ANALYSIS

FIGURE 28 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS

FIGURE 29 SHIMADZU CORPORATION: SWOT ANALYSIS

FIGURE 30 SIEMENS HEALTHINEERS: SWOT ANALYSIS

FIGURE 31 CANON MEDICAL SYSTEMS CORPORATION: SWOT ANALYSIS

FIGURE 32 DILON TECHNOLOGIES: SWOT ANALYSIS

FIGURE 33 PFIZER, INC: SWOT ANALYSIS

FIGURE 34 ICECURE MEDICAL: SWOT ANALYSIS

FIGURE 35 ALPINION MEDICAL SYSTEMS: SWOT ANALYSIS

医療・医薬の最新記事8件